Swiss Geistlich Group Partners with Chinese Medtech Firm Junxiu Biotech, Signaling New Shifts in Oral Regeneration Sector
On June 24, Shandong Junxiu Biotechnology Co., Ltd., a domestic medical device enterprise, officially signed an agreement with the Swiss Geistlich Group, a global leader in oral regeneration, in Yantai, Shandong Province, establishing a strategic partnership. The two parties will engage in in-depth cooperation across multiple dimensions, including commercial collaboration, product research and development, market promotion, and overseas operations, to leverage their respective strengths and achieve win-win outcomes.
Signing Ceremony
Geistlich Pharma AG, a Swiss company specializing in the production of biomaterials for bone, cartilage, and tissue regeneration, was founded in 1851. With subsidiaries in 12 countries and products available in over 100 countries worldwide, it enjoys a renowned reputation as the “Regeneration Expert.” Junxiu Biotechnology is a national high-tech enterprise that has long focused on innovative research and product promotion in the field of regenerative medicine. Neurui®Acellular Matrix Peripheral Nerve Repair Membrane, Pustar®The oral care product series has demonstrated excellent performance in rigorous multi-party testing for safety and efficacy, with its core technologies exhibiting strong competitiveness in the international market.
At the signing ceremony, Diego Gabathuler, CEO of the Geistlich Group, stated that the Chinese market holds significant importance for Geistlich. He noted that Shandong Junxiu Biotechnology Co., Ltd. shares a similar corporate culture and deeply resonant values with Geistlich, making it the perfect partner for Geistlich in the Chinese market. He expressed confidence that this collaboration will drive greater success for oral regeneration initiatives in China.
Gao Xiuyan, Chairman of Junxiu Biotechnology, and Liao Ning, General Manager of Geistlich China, discussed matters of cooperation.
“We are delighted to engage in deep, multi-faceted collaboration with Junxiu Biotechnology. Together, we remain unwaveringly committed to providing the highest-quality products and services to dentists and patients in China,” said Liao Ning, General Manager of Geistlich China, expressing strong confidence in this partnership.
Gao Xiuyan, Chairman of Junxiu Biotechnology, stated that the global medical device industry is currently experiencing robust growth and holds immense potential. Both Junxiu Biotechnology and the Swiss Geistlich Group adhere to a long-term orientation, placing high priority on product quality and evidence-based medicine. Through this collaboration, the two parties will establish a close and enduring partnership, jointly committed to promoting the expansion and development of their products and services in both domestic and international markets.
As a national high-tech enterprise, Junxiu Biotechnology boasts strong R&D capabilities, high innovativeness, and significant growth potential. In 2022, it secured tens of millions of yuan in financing, led by Shenzhen Capital Group (SCGC) and participated by investors such as Qianhai Ark Venture Capital and Huatong Venture Capital. Shao Zhiyong, Deputy General Manager of SCGC’s North China Headquarters, spoke highly of this strategic partnership. In his on-site remarks, he stated that Junxiu Biotechnology operates at the forefront of research, possesses distinct technological advantages, achieves efficient translation of scientific achievements, demonstrates robust R&D strength, maintains a comprehensive quality system, and has a mature commercialization model. He expressed high expectations for the collaboration between Junxiu Biotechnology and the Swiss Geistlich Group.
Currently, a new wave of industrial and technological revolution led by biotechnology is surging. The global medical device industry is at a critical stage of transitioning toward high-quality development with a health-centric focus, while domestic dental restorative material companies are entering an “acceleration phase” of commercialization and international expansion. The formal signing of a cooperation agreement between Junxiu Biotechnology and the Swiss Geistlich Group not only sets a benchmark for international collaboration within the industry but also heralds the further rise of China’s medical device industry on the global stage, injecting robust momentum into the realization of Chinese-style modernization.